WO2020228746A1 - Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide - Google Patents

Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Download PDF

Info

Publication number
WO2020228746A1
WO2020228746A1 PCT/CN2020/090060 CN2020090060W WO2020228746A1 WO 2020228746 A1 WO2020228746 A1 WO 2020228746A1 CN 2020090060 W CN2020090060 W CN 2020090060W WO 2020228746 A1 WO2020228746 A1 WO 2020228746A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluorocyclopropyl
oxadiazol
imidazo
methylphenyl
pyridine
Prior art date
Application number
PCT/CN2020/090060
Other languages
English (en)
French (fr)
Inventor
Xiaoyang Wang
Andreas Kordikowski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112021022685A priority Critical patent/BR112021022685A2/pt
Priority to CN202080050607.4A priority patent/CN114096538A/zh
Priority to AU2020274564A priority patent/AU2020274564A1/en
Priority to MX2021013814A priority patent/MX2021013814A/es
Priority to JP2021567913A priority patent/JP2022533340A/ja
Priority to US17/595,260 priority patent/US20220194936A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to CA3139552A priority patent/CA3139552A1/en
Priority to KR1020217040220A priority patent/KR20220007650A/ko
Priority to SG11202112281UA priority patent/SG11202112281UA/en
Priority to EP20805948.5A priority patent/EP3969453A4/en
Publication of WO2020228746A1 publication Critical patent/WO2020228746A1/en
Priority to IL287877A priority patent/IL287877A/he

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide.
  • the present invention further relates to the process for the preparation of the crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising said crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide and at least one pharmaceutically acceptable excipient.
  • the pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment a mast-cell associated disease, a respiratory disease, an inflammatory disorder, irritable bowel syndrome (IBS) , inflammatory bowel disease (IBD) , an autoimmune disorder, a metabolic disease, a fibrosis disease, a dermatological disease, pulmonary arterial hypertension (PAH) and primary pulmonary hypertension (PPH) .
  • a mast-cell associated disease a respiratory disease
  • IBS irritable bowel syndrome
  • IBD inflammatory bowel disease
  • an autoimmune disorder a metabolic disease
  • a fibrosis disease a dermatological disease
  • PAH pulmonary arterial hypertension
  • PPH primary pulmonary hypertension
  • compositions of the present invention can be used as a medicament for the treatment and/or prophylaxis of asthma, allergic rhinitis, pulmonary arterial hypertension (PAH) , pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, scleroderma, irritable bowel syndrome (IBS) , inflammatory bowel disease (IBD) , urticaria, dermatosis, atopic dermatitis, allergic contact dermatitis, rheumatoid arthritis, multiple sclerosis, melanoma, a gastrointestinal stromal tumor, a mast cell tumor, mastocytosis, anaphylactic syndrome, type I diabetes or type II diabetes.
  • PAH pulmonary arterial hypertension
  • IBS pulmonary arterial hypertension
  • IBD inflammatory bowel disease
  • urticaria dermatosis
  • atopic dermatitis allergic contact dermatitis
  • rheumatoid arthritis multiple sclerosis
  • melanoma
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide is a selective inhibitor of c-kit kinase, useful for the depletion of mast cells and thus is useful for treating a mast-cell associated disease including asthma, allergic rhinitis, pulmonary arterial hypertension (PAH) , pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, scleroderma, irritable bowel syndrome (IBS) , inflammatory bowel disease (IBD) , urticaria, dermatosis, atopic dermatitis, allergic contact dermatitis, rheumatoid arthritis, multiple sclerosis, melanoma, a gastrointestinal stromal tumor, a mast cell tumor, mastocytosis, anaphylactic syndrome, type I diabetes or type II
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide can be represented by the chemical structure as depicted in Formula (A) :
  • WO 2013/033070 A1 generically discloses several acid addition salts of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, such as salts with hydrobromic acid, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, succinic acid, maleic acid, malonic acid, mandelic acid, acetic acid, propionic acid, glycolic acid, oxalic acid, fumaric acid, citric acid, tartaric acid, lactic acid, benzoic acid, salicylic acid, glutamic acid, aspartic acid, toluenesulfonic acid, sulfosalicylic acid, benzenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, naphthalenesulfonic acid,
  • Co-crystals are structurally readily distinguishable from salts because unlike salts, their components are in a neutral state and interact nonionically.
  • co-crystals structurally differ from polymorphs, which are defined as including only single-component crystalline forms that have different arrangements or conformations of the molecules in the crystal lattice
  • co-crystals are structurally more similar to solvates and hydrates, in that both contain more than one component in the crystal lattice and the interaction between these components is nonionic. From a physical chemistry perspective, co-crystals can be viewed as a special case of solvates and hydrates, wherein the second component, the co-crystal former, is nonvolatile. (see also “Regulatory Classification of Pharmaceutical Co-Crystals” , Guidance for Industry, FDA, Revision 1, August 2016) .
  • API active pharmaceutical ingredient
  • solid-state forms of an active pharmaceutical ingredient often possess different physical and chemical properties such as but not limited to dissolution rate, solubility, chemical stability, physical stability, hygroscopicity, melting point, morphology, flowability, bulk density and compressibility.
  • conventional solid-state forms of an API such as polymorphs, pseudopolymorphs (hydrates and solvates) and salts
  • pharmaceutical co-crystals open up further opportunities for customizing the physicochemical properties of APIs with a process or clinical need. For example, they can be tailored to enhance drug product bioavailability and stability and to enhance the processability of APIs during drug product manufacture.
  • the tendency of a drug substance to absorb water from the environment can negatively affect the pharmaceutical behavior and quality of a drug product.
  • Water absorption for example can lead to chemical degradation (e.g. via hydrolysis) , trigger changes of the physical form (e.g. via hydrate formation) , lead to changes in dissolution behavior and influence powder properties such as flowability, compactability, tableting and compression behavior etc.
  • the present invention solves one or more of the above mentioned problems by providing a crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, which is hereinafter also referred to “Form A” .
  • Form A of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide of the present invention possesses favorable physicochemical properties for a drug substance intended for use in an oral solid dosage form. Said properties include chemical stability, physical stability, hygroscopicity, solubility, dissolution, morphology, crystallinity, flowability, compactibility and wettability.
  • the crystalline Form A of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide of the present invention preserves its crystal structure even when subjected to severe temperature and/or humidity stress conditions or when slurried for prolonged time in various solvents.
  • the usage of the thermodynamically stable form of a compound is highly appreciated as polymorphic conversions, which may occur during manufacturing process and storage of a drug substance can be excluded, when the stable form is used. This ensures reliable bioavailability and therefore consistent efficacy of a drug product.
  • the invention also provides a pharmaceutical co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, in particular, the invention provides a pharmaceutical co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid.
  • Form A of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide can be characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (5.0 ⁇ 0.2) ° and (13.2 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Form A of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide can be characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of 6.7 ⁇ 0.2) ° and (18.0 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Form A of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide can be characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (6.7 ⁇ 0.2) ° and (18.0 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • co-crystal refers to crystalline materials composed of two or more different molecular and/or ionic compounds in the same crystal lattice that are associated by nonionic and noncovalent bonds, wherein at least two of the individual molecular and/or ionic compounds are solids at room temperature.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide form A refers to the crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide.
  • Form A of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide can be characterized by having a powder X-ray diffractogram (PXRD) comprising reflections at 2-Theta angles of (13.2 ⁇ 0.2) ° and (19.7 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • PXRD powder X-ray diffractogram
  • room temperature refers to a temperature in the range of from 20 to 30 °C.
  • the term “measured at a temperature in the range of from 20 to 30 °C” refers to a measurement under standard conditions.
  • standard conditions mean a temperature in the range of from 20 to 30 °C, i.e. at room temperature.
  • Standard conditions can mean a temperature of about 22 °C.
  • standard conditions can additionally mean a measurement under 20-50%relative humidity.
  • reflection with regard to powder X-ray diffraction as used herein, means peaks in an X-ray diffractogram, which are caused at certain diffraction angles (Bragg angles) by constructive interference from X-rays scattered by parallel planes of atoms in solid material, which are distributed in an ordered and repetitive pattern in a long-range positional order.
  • a solid material is classified as crystalline material, whereas amorphous material is defined as solid material, which lacks long-range order and only displays short-range order, thus resulting in broad scattering.
  • long-range order e.g.
  • the term “essentially the same” with reference to powder X-ray diffraction means that variabilities in reflection positions and relative intensities of the reflections are to be taken into account.
  • a typical precision of the 2-Theta values is in the range of ⁇ 0.2° 2-Theta, preferably in the range of ⁇ 0.1° 2-Theta.
  • a reflection that usually appears at 3.6°2-Theta for example can appear between 3.4° and 3.8° 2-Theta, preferably between 3.5 and 3.7° 2-Theta on most X-ray diffractometers under standard conditions.
  • relative reflection intensities will show inter-apparatus variability as well as variability due to degree of crystallinity, preferred orientation, sample preparation and other factors known to those skilled in the art and should be taken as qualitative measure only.
  • solid form or “solid-state form” as used herein refers to any crystalline and/or amorphous phase of a compound.
  • Crystalline phases include anhydrous/non-solvated forms of a compound and their polymorphs, hydrates and solvates of a compound and their polymorphs, salts and co-crystals of a compound and any mixtures thereof.
  • amorphous refers to a solid form of a compound that is not crystalline. An amorphous compound possesses no long-range order and does not display a definitive X-ray diffraction pattern with reflections.
  • polymorph refers to crystalline forms having the same chemical composition but different spatial arrangements of the molecules, atoms, and/or ions forming the crystal.
  • anhydrous or “anhydrate” as used herein refer to a crystalline solid where no water is cooperated in or accommodated by the crystal structure.
  • Anhydrous forms may still contain residual water, which is not part of the crystal structure but may be adsorbed on the surface or absorbed in disordered regions of the crystal.
  • an anhydrous form does not contain more than 2.0 weight%, preferably not more than 1.0 weight%based on the weight of the crystalline form.
  • the water content can be determined by Karl-Fischer Coulometry and/or by thermogravimetric analysis (TGA) , e.g. by determining the mass loss in the range of from 25 to 180 °C, 190 °C or 200 °C at a heating rate of 10 °C/min.
  • hydrate refers to a crystalline solid where either water is cooperated in or accommodated by the crystal structure e.g. is part of the crystal structure or entrapped into the crystal (water inclusions) .
  • water can be present in a stoichiometric or non-stoichiometric amount.
  • the hydrate may be referred to by adding greek numeral prefixes.
  • a hydrate may be referred to as a hemihydrate or as a monohydrate depending on the water/compound stoichiometry.
  • the water content can be measured, for example, by Karl-Fischer-Coulometry.
  • dehydrating or “dehydration” as used herein, describe the at least partial removal of water from the crystal structure of the host molecule.
  • solvate refers to a crystalline solid were either one or more organic solvent (s) is/are cooperated in or accommodated by the crystal structure e.g. is/are part of the crystal structure or entrapped into the crystal (water inclusions) . Thereby, the one or more organic solvent (s) can be present in a stoichiometric or non-stoichiometric amount.
  • the solvate may be referred to by adding greek numeral prefixes.
  • a solvate may be referred to as a hemisolvate or as a monosolvate depending on the solvent (s) /compound stoichiometry.
  • the solvent content can be measured, for example, by GC, NMR, SXRD and/or TGA/MS.
  • non-solvated when talking about a crystalline solid indicates that no organic solvent is cooperated in or accommodated by the crystal structure.
  • Non-solvated forms may still contain residual organic solvents, which are not part of the crystal structure but may be adsorbed on the surface or absorbed in disordered regions of the crystal.
  • a non-solvated form does not contain more than 2.0 weight%, preferably not more than 1.0 weight%, and most preferably not more than 0.5 weight%of organic solvents, based on the weight of the crystalline form.
  • the organic solvent content can be determined by thermogravimetric analysis (TGA) , e.g. by determining the mass loss in the range of from 25 to 180 °C, 190 °C or 200 °C at a heating rate of 10 °C/min or by 1H-NMR.
  • TGA thermogravimetric analysis
  • isostructural solvate refers to solvates having the same space group with only small distortions of the unit cell dimensions and the same type of molecular network of the host molecule. Isostructural solvates as defined herein, differ in the type of organic solvent (s) present as guest molecule (s) .
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A may be referred to herein as being characterized by a powder X-ray diffractogram "as shown in" a figure.
  • the person skilled in the art understands that factors such as variations in instrument type, response and variations in sample directionality, sample concentration, sample purity, sample history and sample preparation may lead to variations, for example relating to the exact reflection or peak positions and intensities.
  • a comparison of the graphical data in the figures herein with the graphical data generated for an unknown physical form and the confirmation that two sets of graphical data relate to the same crystal form is well within the knowledge of a person skilled in the art.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA may be referred to herein as being characterized by a powder X-ray diffractogram "as shown in" a figure.
  • the person skilled in the art understands that factors such as variations in instrument type, response and variations in sample directionality, sample concentration, sample purity, sample history and sample preparation may lead to variations, for example relating to the exact reflection or peak positions and intensities.
  • a comparison of the graphical data in the figures herein with the graphical data generated for an unknown physical form and the confirmation that two sets of graphical data relate to the same crystal form is well within the knowledge of a person skilled in the art.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HB may be referred to herein as being characterized by a powder X-ray diffractogram "as shown in" a figure.
  • the person skilled in the art understands that factors such as variations in instrument type, response and variations in sample directionality, sample concentration, sample purity, sample history and sample preparation may lead to variations, for example relating to the exact reflection or peak positions and intensities.
  • a comparison of the graphical data in the figures herein with the graphical data generated for an unknown physical form and the confirmation that two sets of graphical data relate to the same crystal form is well within the knowledge of a person skilled in the art.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal may be referred to herein as being characterized by a powder X-ray diffractogram (PXRD) "as shown in” a figure.
  • PXRD powder X-ray diffractogram
  • the person skilled in the art understands that factors such as variations in instrument type, response and variations in sample directionality, sample concentration, sample purity, sample history and sample preparation may lead to variations, for example relating to the exact reflection or peak positions and intensities.
  • a comparison of the graphical data in the figures herein with the graphical data generated for an unknown physical form and the confirmation that two sets of graphical data relate to the same crystal form is well within the knowledge of a person skilled in the art.
  • mother liquor refers to the solution remaining after crystallization of a solid from said solution.
  • a “predetermined amount” as used herein with regard to N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or co-crystal of the present invention refers to the initial amount of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or co-crystal used for the preparation of a pharmaceutical composition having a desired dosage strength of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide.
  • the term “effective amount” in conjunction with the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3- carboxamide Form A of the present invention encompasses an amount of the the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or co-crystal which causes the desired therapeutic or prophylactic effect.
  • the term “about” means within a statistically meaningful range of a value. Such a range can be within an order of magnitude, typically within 10%, more typically within 5%, even more typically within 1%and most typically within 0.1%of the indicated value or range. Sometimes, such a range can lie within the experimental error, typical of standard methods used for the measurement and/or determination of a given value or range.
  • the term “essentially free of any other solid-state form” with reference to the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention means that the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A contains at most 20 weight%, preferably at most 10 weight%, more preferably at most 5 weight%, 4 weight%, 3 weight%, 2 weight%or 1 weight%of any other solid-state form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphen
  • pharmaceutically acceptable excipient refers to substances, which do not show a significant pharmacological activity at the given dose and that are added to a pharmaceutical composition in addition to the active pharmaceutical ingredient. Excipients may take the function of vehicle, diluent, release agent, disintegrating agent, dissolution modifying agent, absorption enhancer, stabilizer or a manufacturing aid among others. Excipients may include fillers (diluents) , binders, disintegrants, lubricants and glidants.
  • filler or “diluent” as used herein refer to substances that are used to dilute the active pharmaceutical ingredient prior to delivery. Diluents and fillers can also serve as stabilizers.
  • binder refers to substances which bind the active pharmaceutical ingredient and pharmaceutically acceptable excipient together to maintain cohesive and discrete portions.
  • disintegrant or “disintegrating agent” as used herein refers to substances which, upon addition to a solid pharmaceutical composition, facilitate its break-up or disintegration after administration and permits the release of the active pharmaceutical ingredient as efficiently as possible to allow for its rapid dissolution.
  • lubricant refers to substances which are added to a powder blend to prevent the compacted powder mass from sticking to the equipment during tableting or encapsulation process. They aid the ejection of the tablet from the dies and can improve powder flow.
  • glidant refers to substances which are used for tablet and capsule formulations in order to improve flow properties during tablet compression and to produce an anti-caking effect.
  • photostabilizing agent refers to substances which prevent or reduce the photodegradation or photodecomposition of the active pharmaceutical ingredient upon light exposure.
  • the photostabilizing agent functions to prevent or reduce the formation of photodegradation products.
  • the photostabilizing agent prevents or reduces the photodegradation of the light sensitive active pharmaceutical ingredient by blocking or reducing the exposure of the molecule to light within a wavelength range.
  • the term “effective amount” in conjunction with a photostabilizing agent encompasses an amount of the photostabilizing agent which is sufficient to prevent or reduce the photodegradation of the active pharmaceutical ingredient, such that the amount of photodegradation products that is produced is limited to a desired maximum level under specific light conditions.
  • Figure 1 illustrates a representative powder X-ray diffractogram (PXRD) curve of Form A of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide according to the present invention.
  • the x-axis shows the scattering angle in °2-Theta
  • the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
  • Figure 2 illustrates a representative differential scanning calorimetry (DSC) curve of Form A of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide according to the present invention.
  • the x-axis shows the temperature in degree Celsius (°C)
  • the y-axis shows the heat flow rate in Watt per gram (W/g) with endothermic peaks going up.
  • Figure 3 illustrates a representative thermogravimetric analysis (TGA) curve of Form A of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2- a] pyridine-3-carboxamide according to the present invention.
  • the x-axis shows the temperature in degree Celsius (°C)
  • the y-axis shows the mass (loss) of the sample in weight percent (weight%) .
  • Figure 4 illustrates a representative powder X-ray diffractogram (PXRD) curve Form HA of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide according to the present invention.
  • the x-axis shows the scattering angle in °2-Theta
  • the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
  • Figure 5 illustrates a representative differential scanning calorimetry (DSC) curve of Form HA N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide according to the present invention.
  • the x-axis shows the temperature in degree Celsius (°C)
  • the y-axis shows the heat flow rate in Watt per gram (W/g) with endothermic peaks going up.
  • Figure 6 illustrates a representative thermogravimetric analysis (TGA) curve of Form HA of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide according to the present invention.
  • the x-axis shows the temperature in degree Celsius (°C)
  • the y-axis shows the mass (loss) of the sample in weight percent (weight%) .
  • Figure 7 illustrates a representative powder X-ray diffractogram (PXRD) curve Form HB of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide according to the present invention.
  • the x-axis shows the scattering angle in °2-Theta
  • the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
  • Figure 8 illustrates a representative differential scanning calorimetry (DSC) curve of Form HB of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide according to the present invention.
  • the x-axis shows the temperature in degree Celsius (°C)
  • the y-axis shows the heat flow rate in Watt per gram (W/g) with endothermic peaks going up.
  • Figure 9 illustrates a representative thermogravimetric analysis (TGA) curve of Form HB of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide according to the present invention.
  • the x-axis shows the temperature in degree Celsius (°C)
  • the y-axis shows the mass (loss) of the sample in weight percent (weight%) .
  • Figure 10 illustrates a representative powder X-ray diffractogram (PXRD) of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal according to the present invention.
  • the x-axis shows the scattering angle in °2-Theta
  • the y-axis shows the intensity of the scattered X-ray beam in counts of detected photons.
  • Figure 11 illustrates a representative differential scanning calorimetry (DSC) curve of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal according to the present invention.
  • the x-axis shows the temperature in degree Celsius (°C)
  • the y-axis shows the heat flow rate in Watt per gram (W/g) .
  • Figure 12 illustrates a representative thermogravimetric analysis (TGA) curve of the the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal according to the present invention.
  • TGA thermogravimetric analysis
  • Figure 13 illustrates the NMR of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A obtained in d6-DMSO.
  • Figure 14 illustrates the NMR of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal.
  • the present invention provides crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide as the active pharmaceutical ingredient, in particular crystalline Form A of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide and two hydrate forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide; Form HA and Form HB.
  • Form A of the present invention is physically stable toward temperature stress e.g. it shows no thermal events in a DSC experiment until it starts to melt at about 175°C ( Figure 2) .
  • a TGA experiment performed with the Form A of the present invention revealed no significant mass loss until melting ( Figure 3) , which indicates the presence of an anhydrous and non-solvated solid-state form.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention shows advantageous dissolution behavioiur, good chemical stability e.g. against photodegradation and is characterized by excellent powder properties such as good flowability, high bulk density and good compressibility.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention may be characterized by analytical methods well known in the field of the pharmaceutical industry for characterizing crystalline solids. Such methods comprise but are not limited to powder and single X-ray diffraction, Fourier transform and Raman spectroscopy, DSC, TGA and GMS.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA of the present invention may be characterized by one of the aforementioned analytical methods or by combining two or more of them.
  • Form HA shows melting at about 87 °C, melting at about 125 °C followed by recrystallization, melting at about 165 °C followed by recrystallization, and melting again with a final melting point of about 175 °C.
  • a DSC experiment Form HB shows melting at about 110 °C, followed by recrystallisation, melting at about 125 °C followed by recrystallization, melting at about 165 °C followed by recrystallization, and melting again with a final melting point of about 175 °C.
  • a TGA experiment performed with the Form HA of the present invention revealed about 5 %mass loss until melting
  • Form HB revealed about a 4.5 %mass loss until melting.
  • Form HA and Form HB of the present invention may be characterized by analytical methods well known in the field of the pharmaceutical industry for characterizing crystalline solids. Such methods comprise but are not limited to powder and single X-ray diffraction, Fourier transform and Raman spectroscopy, DSC, TGA and GMS.
  • the crystalline forms HA and HB of the present invention may be characterized by one of the aforementioned analytical methods or by combining two or more of them.
  • the crystalline forms of the present invention may be characterized by any one of the following embodiments or by combining two or more of the following embodiments.
  • Embodiment 1 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, herein refered to as “Form A” , where N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide can be represented by the chemical structure as depicted in Formula A:
  • Embodiment 2 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, herein refered to as “Form HA” .
  • Embodiment 3 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, herein refered to as “Form HB” .
  • Embodiment 4 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of:
  • Embodiment 5 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (5.0 ⁇ 0.2) ° and (22.1 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 6 The crystalline form Embodiment 5 characterized by having a powder X-ray diffractogram comprising additional reflections at 2-Theta angles of (8.8 ⁇ 0.2) °, (17.4 ⁇ 0.2) °, (17.6 ⁇ 0.2) °, and (24.5 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 7 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of:
  • Embodiment 8 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (5.0 ⁇ 0.1) ° and (22.1 ⁇ 0.1) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 9 The crystalline form Embodiment 8 characterized by having a powder X-ray diffractogram comprising additional reflections at 2-Theta angles of (8.8 ⁇ 0.1) °, (17.4 ⁇ 0.1) °, (17.6 ⁇ 0.1) ° and (24.5 ⁇ 0.1) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 10 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram essentially the same as shown in figure 1 of the present invention, when measured at room temperature with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 11 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized in that the crystalline form is anhydrous.
  • Embodiment 12 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized in that the crystalline form is non-solvated.
  • Embodiment 13 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a differential scanning calorimetry curve comprising an endothermic peak having an onset temperature of (175.0 ⁇ 0.5) °C, when measured at a heating rate of 10 K/min.
  • Embodiment 14 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a differential scanning calorimetry curve comprising an endothermic peak having a peak temperature of (175.2 ⁇ 0.5) °C, when measured at a heating rate of 10 K/min.
  • Embodiment 15 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a thermogravimetric analysis curve showing a mass loss of 0.01 weight%or less, preferably of 0.007 weight%or less based on the weight of the crystalline form, when heated from room temperature to 180 °C at a rate of 10 K/min.
  • Embodiment 16 A crystalline form of of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a thermogravimetric analysis curve showing a mass loss of not more than 0.01 weight%, based on the weight of the crystalline form, when heated from 30 °C to 180 °C at a rate of 10 K/min.
  • Embodiment 17 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of:
  • Embodiment 18 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (8.0 ⁇ 0.2) ° and (32.6 ⁇ 0.2) °; when measured at RT with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 19 The crystalline form Embodiment 18 characterized by having a powder X-ray diffractogram comprising additional reflections at 2-Theta angles of (12.8 ⁇ 0.2) °, (21.6 ⁇ 0.2) ° and (25.9 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °Cwith Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 20 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of:
  • Embodiment 21 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (8.0 ⁇ 0.1) ° and (32.6 ⁇ 0.1) °; when measured at RT with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 22 The crystalline form Embodiment 21 characterized by having a powder X-ray diffractogram comprising additional reflections at 2-Theta angles of (12.8 ⁇ 0.1) °, (21.6 ⁇ 0.1) ° and (25.9 ⁇ 0.1) °, when measured at a temperature in the range of from 20 to 30 °Cwith Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 23 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram essentially the same as shown in figure 4 of the present invention, when measured at room temperature with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 24 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a differential scanning calorimetry curve essentially the same as shown in figure 5 when measured with a DSC at a heating rate of 10 K/min.
  • Embodiment 25 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a thermogravimetric analysis curve essentially the same as shown in figure 6 when heated from room temperature to 112 °C at a rate of 10 K/min.
  • Embodiment 26 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a thermogravimetric analysis curve showing a mass loss of 5.5 weight%or less, preferably of 5.3 weight%or less based on the weight of the crystalline form, when heated from room temperature to 112 °C at a rate of 10 K/min.
  • Embodiment 27 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a thermogravimetric analysis curve showing a mass loss of 5.5 weight%or less, preferably of 5.3 weight%or less based on the weight of the crystalline form, when heated from 30 °C to 112 °C at a rate of 10 K /min.
  • Embodiment 28 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of:
  • Embodiment 29 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (23.8 ⁇ 0.2) ° and (29.7 ⁇ 0.2) °, when measured at RT with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 30 The crystalline form Embodiment 18 characterized by having a powder X-ray diffractogram comprising additional reflections at 2-Theta angles of (23.5 ⁇ 0.2) °, (23.8 ⁇ 0.2) ° and (28.7 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °Cwith Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 31 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, Form HB, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of:
  • Embodiment 32 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (23.8 ⁇ 0.1) ° and (29.7 ⁇ 0.1) °, when measured at RT with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 33 The crystalline form Embodiment 18 characterized by having a powder X-ray diffractogram comprising additional reflections at 2-Theta angles of (23.5 ⁇ 0.1) °, (23.8 ⁇ 0.1) ° and (28.7 ⁇ 0.1) °, when measured at a temperature in the range of from 20 to 30 °Cwith Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 34 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a powder X-ray diffractogram essentially the same as shown in figure 7 of the present invention, when measured at room temperature with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • Embodiment 35 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a differential scanning calorimetry curve essentially the same as shown in figure 8 when measured with DSC at a heating rate of 10 K/min.
  • Embodiment 36 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a thermogravimetric analysis curve essentially the same as shown in figure 9 when heated from room temperature to 100 °C at a rate of 10 K/min.
  • Embodiment 37 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a thermogravimetric analysis curve showing a mass loss of 5.0 weight%or less, preferably of 4.5 weight%or less based on the weight of the crystalline form, when heated from room temperature to 100 °C at a rate of 10 K/min.
  • Embodiment 38 A crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, characterized by having a thermogravimetric analysis curve showing a mass loss of 5.0 weight%or less, preferably of 4.5 weight%or less based on the weight of the crystalline form, when heated from 30 °C to 100 °C at a rate of 10 K/min.
  • Form HA and Form HB of free form N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide show thermal events such as dehydration/desolvation and recrystallization events during DSC experiments, indicating solvent/water losses and phase transformations.
  • Form A and Form B of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide appear to at least partially transform to N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A during DSC experiments, which is indicated by the final melting endotherm having a peak temperature of about 175 °C, which can be assigned to the melting of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A.
  • the thermal stability of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention is superior compared to the hydrated Forms HA and HB of N- (5- (5- ( (1R, 2S) -2- fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide.
  • the present invention provides a pharmaceutical co-crystal composed of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide as the active pharmaceutical ingredient and fumaric acid as the co-crystal former.
  • the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention is physically stable toward temperature stress e.g. it shows no thermal events in a DSC experiment until it starts to melt at about 229 °C. Moreover, a TGA experiment performed with the co-crystal of the present invention revealed no significant mass loss until melting, which indicates the presence of an anhydrous and non-solvated solid-state form.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention shows advantageous dissolution behavioiur, good chemical stability e.g. against photodegradation and is characterized by excellent powder properties such as good flowability, high bulk density and good compressibility.
  • the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention may be characterized by analytical methods well known in the field of the pharmaceutical industry for characterizing crystalline solids. Such methods comprise but are not limited to powder and single X-ray diffraction, Fourier transform and Raman spectroscopy, DSC, TGA and GMS.
  • the co-crystal of the present invention may be characterized by one of the aforementioned analytical methods or by combining two or more of them.
  • the co-crystal of the present invention may be characterized by any one of the following embodiments or by combining two or more of the following embodiments.
  • Embodiment 39 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid.
  • Embodiment 40 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid characterized by having the chemical structure as depicted in Formula B
  • n is in the range of from 1.8 to 2.2, preferably of from 1.9 to 2.1, even more preferably of from 1.95 to 2.05 and most preferably n is 2.0.
  • Embodiment 41 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid wherein the molar ratio of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide to fumaric acid is in the range of from 1.8 to 2.2 : 1.
  • Embodiment 42 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid wherein the molar ratio of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide to fumaric acid is in the range of from preferably of from 1.9 to 2.1 : 1.
  • Embodiment 43 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid wherein the molar ratio of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide to fumaric acid is in the range of from even more preferably of from 1.95 to 2.05 : 1.
  • Embodiment 44 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid wherein the molar ratio of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide to fumaric acid is in the range of from and most preferably 2: 1.
  • Embodiment 45 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid characterized by having a powder X-ray diffractogram (PXRD) comprising reflections at 2-Theta angles of:
  • PXRD powder X-ray diffractogram
  • Embodiment 46 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid characterized by having a powder X-ray diffractogram (PXRD) comprising reflections at 2-Theta angles of (12.3 ⁇ 0.2) ° and (27.3 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • PXRD powder X-ray diffractogram
  • Embodiment 47 The co-crystal of Embodiment 8 characterized by having a powder X-ray diffractogram (PXRD) comprising additional reflections at 2-Theta angles of (14.9.0 ⁇ 0.2) °, (16.5 ⁇ 0.2) °, (21.2 ⁇ 0.2) ° and (25.4 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • PXRD powder X-ray diffractogram
  • Embodiment 48 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with Fumaric acid characterized by having a powder X-ray diffractogram (PXRD) comprising reflections at 2-Theta angles of:
  • PXRD powder X-ray diffractogram
  • Embodiment 49 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid characterized by having a powder X-ray diffractogram (PXRD) comprising reflections at 2-Theta angles of (12.3 ⁇ 0.1) ° and (27.3 ⁇ 0.1) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • PXRD powder X-ray diffractogram
  • Embodiment 50 The co-crystal of Embodiment 11 characterized by having a powder X-ray diffractogram (PXRD) comprising additional reflections at 2-Theta angles of (14.9.0 ⁇ 0.1) °, (16.5 ⁇ 0.1) °, (21.2 ⁇ 0.1) ° and (25.4 ⁇ 0.1) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • PXRD powder X-ray diffractogram
  • Embodiment 51 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid, characterized by having a powder X-ray diffractogram (PXRD) essentially the same as shown in figure 1 of the present invention, when measured at room temperature with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • PXRD powder X-ray diffractogram
  • Embodiment 52 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid characterized in that the co-crystal is anhydrous.
  • Embodiment 53 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid characterized in that the co-crystal is non-solvated.
  • Embodiment 54 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid, characterized by having a differential scanning calorimetry (DSC) curve comprising an endothermic peak, preferably a single endothermic peak, having an onset temperature of (227 ⁇ 1) °C, when measured with DSC at a heating rate of 10 K/min.
  • DSC differential scanning calorimetry
  • Embodiment 55 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid, characterized by having a differential scanning calorimetry (DSC) curve comprising an endothermic peak, preferably a single endothermic peak, having a peak temperature of (229 ⁇ 1) °C, when measured with DSC at a heating rate of 10 K/min.
  • DSC differential scanning calorimetry
  • Embodiment 56 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid, characterized by having a thermogravimetric analysis (TGA) curve showing a mass loss of 1.5 weight%or less, preferably of 1.4 weight%or less based on the weight of the co-crystal, when heated from RT to 150 °C at a rate of 10 K/min.
  • TGA thermogravimetric analysis
  • Embodiment 57 A co-crystal of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide with fumaric acid, characterized by having a thermogravimetric analysis (TGA) curve showing a mass loss of 2.5 weight%or less, preferably of 2.0 weight%or less based on the weight of the co-crystal, when heated from RT to 200 °C at a rate of 10 K/min.
  • TGA thermogravimetric analysis
  • Form A and Form B of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide appear to at least partially transform to N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A during DSC experiments, which is indicated by the final melting endotherm having a peak temperature of about 175 °C, which can be assigned to the melting of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A.
  • the thermal stability of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention is superior compared to the hydrated Forms HA and HB of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide.
  • the present invention relates to a composition
  • a composition comprising a crystalline form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, where the crystalline form can be Form A, Form HA or Form HB or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention as defined in any of the embodiments described above.
  • the present invention relates to a composition
  • a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention as defined in any of the embodiments described above, said composition being essentially free of any other solid-state form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide can be Form HA of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide which has a PXRD comprising amongst others characteristic reflections at 2-Theta angles of (12.8 ⁇ 0.2) ° and (13.6 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • any other solid-state form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide can be Form HB of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide which has a PXRD comprising amongst others characteristic reflections at 2-Theta angles of (6.7 ⁇ 0.2) ° and (18.0 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • composition comprising N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, preferably the any other solid-state form of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide is form A.
  • the present invention relates to a composition
  • a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention as defined in any of the embodiments described above, said composition having a PXRD comprising no reflections at 2-Theta angles of (12.8 ⁇ 0.2) ° and (13.6 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm, or said composition having a PXRD comprising no reflections at 2-Theta angles of (6.7 ⁇ 0.2) °and (18.0 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm, or
  • the present invention relates to a composition
  • a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention as defined in any of the embodiments described above, said composition comprising at most 20 weight%, 10 weight%, 5 weight%, 2 weight%or 1 weight%of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA , based on the weight of the composition, wherein Form HA is characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (12.8 ⁇ 0.2) ° and (13.6 ⁇ 0.2) °,
  • the present invention relates to a composition
  • a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HB of the present invention as defined in any of the embodiments described above, said composition comprising at most 20 weight%, 10 weight%, 5 weight%, 2 weight%or 1 weight%of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA , based on the weight of the composition, wherein Form HA is characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (6.7 ⁇ 0.2) ° and (18.0 ⁇ 0.2) °
  • the present invention relates to a composition
  • a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention as defined in any of the embodiments described above, said composition having a powder X-ray diffractogram (PXRD) comprising no reflections at 2-Theta angles of (13.2 ⁇ 0.2) ° and (19.7 ⁇ 0.2) °, when measured at a temperature in the range of from 20 to 30 °C with Cu-Kalpha radiation having a wavelength of 0.15406 nm.
  • PXRD powder X-ray diffractogram
  • the present invention relates to a composition
  • a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention as defined in any of the embodiments described above, said composition comprising at most 20 weight%, 10 weight%, 5 weight%, 2 weight%or 1 weight%of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A , based on the weight of the composition, wherein Form A is characterized by having a powder X-ray diffractogram (PXRD) comprising reflections at 2-Theta angles of ( (13.2 ⁇ 0.2) °
  • the invention in another embodiment, relates to a composition
  • a composition comprising at least 90 w-%, including at least 90, 91, 92, 93, 94, 95, 96, 97, 98 and 99 w-%, and also including equal to about 100 w-%of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal as defined in any one of the embodiments described above, based on the total weight of the composition.
  • the remaining material may comprise other solid form (s) of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide, and/or reaction impurities and/or processing impurities arising from the preparation of the composition.
  • the present invention relates to a process for the preparation of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention or the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A as defined in any one of the aspects and their corresponding embodiments described above comprising:
  • step (ii) dissolving N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide provided in step (i) in a solvent under mechanical stirring at elevated temperature;
  • step (iv) separating at least a part of the crystals obtained in step (iii) from the mother liquor;
  • step (v) optionally washing the isolated crystals obtained in step (iv) ;
  • step (vi) drying the crystals obtained in step (iii) or (iv) .
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide can for example be prepared according to the procedure provided in example F110 of WO 2013/033070 A1.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide may be applied as crystalline and/or amorphous material in step (i) of the above described procedure.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide is dissolved in a solvent while stirring, with the resulting N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide being in a concentration in the range of from about 20 to 60 g/L, preferably the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide concentration in the solution provided in (ii) is a concentration in the range of from about 30 to 60 g/L, more
  • the solvent used in the solution provided in (ii) is 2-propanol, acetone, methyl tert-butyl ether (MTBE) , 95%ethanol or dichloromethane (DCM) .
  • the solvent used in the solution provided in (ii) is 2-propanol.
  • the dissolution step (ii) can involve any kind of movement of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide suspended in the solvent caused by, but not limited to e.g. agitation, mixing, shaking, vibration, sonication, wet milling and the like.
  • the dissolution step (ii) is conducted at elevated temperature for example at a temperature in the range of from about 40 to 80 °C, and then the resulting solution is allowed to cool to room temperature.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide provided in (i) is dissolved in a solvent at elevated temperature for example at a temperature in the range of from about 50 to 80 °Cunder mechanical stirring, and then continually stirred for 3-24 hours as the soultion cools to room temperature.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide provided in (i) is dissolved in a solvent at elevated temperature for example at a temperature in the range of from about 60 to 80 °C under mechanical stirring, and then continually stirred for 3-24 hours as the soultion cools to room temperature.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide provided in (i) is dissolved in a solvent at 70 °C under mechanical stirring, and then continually stirred for 3-24 hours as the soultion cools to room temperature.
  • Steps (ii) to (iii) may be conducted for a time sufficient that at least a substantial part, preferably all of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide starting material has converted to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention.
  • step (ii) is performed for a period in the range of from several hours to several days.
  • Step (ii) may for example be performed for a period in the range of from 2 hours to 7 days. More preferably step (ii) is performed for a period in the range of from 2 hours to 40 hours. Most preferably step (ii) is performed for a period in the range of from 3 hours to 30 hours.
  • step (iii) is performed for a period in the range of from several hours to several days.
  • Step (iii) may for example be performed for a period in the range of from 2 hours to 7 days. More preferably step (iii) is performed for a period in the range of from 2 hours to 40 hours.
  • step (iii) is performed for a period in the range of from 3 hours to 30 hours.
  • the skilled person may monitor the conversion of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2- methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention by withdrawing samples from the slurry and analyzing the samples by e.g. powder X-ray diffraction.
  • the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention is obtained or preferably obtained in essentially pure form, at least a part of the crystals may be optionally separated from the mother liquor.
  • the crystals are separated from their mother liquor by any conventional method such as filtration, centrifugation, solvent evaporation or decantation, more preferably by filtration or centrifugation and most preferably by filtration.
  • the isolated crystals are washed with at least one solvent selected from the group consisting of 2-propanol, acetone, methyl tert-butyl ether (MTBE) , 95%ethanol or dichloromethane (DCM) .
  • 2-propanol is used.
  • the obtained crystals may then optionally be dried. Drying may be performed at a temperature in the range of from about 20 to 80 °C, preferably in the range of from about 20 to 70 °C and most preferably drying is performed at 60 °C. Drying may be performed for a period in the range of from about 1 to 72 hours, preferably of from about 2 to 48 hours, more preferably of from about 4 to 36 hours and most preferably of from about 6 to 24 hours. Drying may be performed at ambient pressure and/or under reduced pressure. Preferably, drying is performed at a pressure of about 100 mbar or less, more preferably of about 50 mbar or less and most preferably of about 30 mbar or less, for example a vacuum of about 25 mbar is applied for drying.
  • the present invention relates to a process for the preparation of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention or the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal as defined in any one of the aspects and their corresponding embodiments described above comprising:
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide can for example be prepared according to the procedure provided in example F110 of WO 2013/033070 A1.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide may be applied as crystalline and/or amorphous material in step (a) of the above described procedure.
  • Suitable crystalline forms which may be used are for example N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide form A.
  • the molar ratio of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide to fumaric acid in the powder mixture is in the range of from 1.0: 0.4 to 1.0: 1.2, preferably of from 1.0 : 0.4 to 1.0: 1.1, more preferably of from 1.0: 0.4 to 1.0: 1.05, even more preferably of from 1.0: 0.5 to 1.0: 1.0. and most preferably the molar ratio is 1.0: 0.5.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide being in a concentration in the range of from about 20 to 60 g/L, preferably the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide concentration in the slurry provided in (a) is a concentration in the range of from about 30 to 60 g/L, more preferably the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a]
  • the fumaric acid concentration in the slurry provided in (a) is in a concentration in the range of from about 2.5 to 22 g/L, preferably the fumaric acid concentration in the slurry provided in (a) is in a concentration in the range of from about 3.5 to 22 g/L, more preferably the fumaric acid concentration in the slurry provided in (a) is in a concentration in the range of from about 5 to 22 g/L, even more preferably the fumaric acid concentration in the slurry provided in (a) is in a concentration in the range of from about 5 to 10 g/L, and most preferably the fumaric acid concentration in the slurry provided in (a) is about 7.5 g/L.
  • the solvent used in the suspension provided in (a) is 2-propanol, acetone, methyl tert-butyl ether (MTBE) , 95%ethanol or dichloromethane (DCM) .
  • the solvent used in the suspension provided in (a) is 2-propanol.
  • Slurrying encompasses any kind of movement of the powder mixture suspended in solvent caused by, but not limited to e.g. agitation, stirring, mixing, shaking, vibration, sonication, wet milling and the like.
  • the powder mixture provided in (a) is initially slurried at room temperature, further slurrying is conducted at elevated temperature for example at a temperature in the range of from about 40 to 80 °C, and then further slurrying is conducted as the slurry cools to room temperature.
  • the powder mixture provided in (a) is initially slurried by mechanical stirring at room temperature, further slurried at elevated temperature for example at a temperature in the range of from about 50 to 80 °C, and then further slurrying is conducted as the slurry cools to room temperature. More preferably, the powder mixture provided in (a) is initially slurried by mechanical stirring at room temperature, further slurried at elevated temperature for example at a temperature in the range of from about 60 to 80 °C, and then further slurrying is conducted as the slurry cools to room temperature. Most preferably, the powder mixture provided in (a) is initially slurried by mechanical stirring at room temperature, further slurried at 70 °C, and then further slurrying is conducted as the slurry cools to room temperature.
  • Slurrying may be conducted for a time sufficient that at least a substantial part, preferably all of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide starting material has converted to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention.
  • Preferably slurrying is performed for a period in the range of from several hours to several days.
  • Slurrying may for example be performed for a period in the range of from 2 hours to 7 days. More preferably slurrying is performed for a period in the range of from 2 hours to 40 hours. Most preferably slurrying is performed for a period in the range of from 3 hours to 30 hours.
  • the skilled person may monitor the conversion of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention by withdrawing samples from the slurry and analyzing the samples by e.g. powder X-ray diffraction.
  • the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention is obtained or preferably obtained in essentially pure form, at least a part of the crystals may be optionally separated from the mother liquor.
  • the crystals are separated from their mother liquor by any conventional method such as filtration, centrifugation, solvent evaporation or decantation, more preferably by filtration or centrifugation and most preferably by filtration.
  • the isolated crystals are washed with at least one solvent selected from the group consisting of 2-propanol, acetone, methyl tert-butyl ether (MTBE) , 95%ethanol or dichloromethane (DCM) .
  • 2-propanol is used.
  • the obtained crystals may then optionally be dried. Drying may be performed at a temperature in the range of from about 20 to 80 °C, preferably in the range of from about 20 to 70 °C and most preferably drying is performed at 60 °C. Drying may be performed for a period in the range of from about 1 to 72 hours, preferably of from about 2 to 48 hours, more preferably of from about 4 to 36 hours and most preferably of from about 6 to 24 hours. Drying may be performed at ambient pressure and/or under reduced pressure. Preferably, drying is performed at a pressure of about 100 mbar or less, more preferably of about 50 mbar or less and most preferably
  • the present invention relates to the use of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention or the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention or the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclo
  • the at least one pharmaceutically acceptable excipient which is comprised in the pharmaceutical composition of the present invention, is preferably selected from the group consisting of fillers, diluents, binders, disintegrants, lubricants, glidants and combinations thereof.
  • the pharmaceutical composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3- carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal or the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl
  • the tablet may be prepared by mixing the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal or the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-
  • the capsule may be prepared by mixing the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal or the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-
  • the present invention relates to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-y
  • the present invention relates to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-y
  • PAH pulmonary arterial hypertension
  • IBS pulmonary arterial hypertension
  • IBD inflammatory bowel disease
  • urticaria dermatosis
  • atopic dermatitis allergic contact dermatitis
  • rheumatoid arthritis multiple sclerosis
  • melanoma a gastrointestinal stromal tumor
  • a mast cell tumor
  • the present invention relates to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2- methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-
  • the present invention relates to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-y
  • the present invention relates to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-y
  • the present invention relates to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-y
  • the present invention relates to the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-y
  • the present invention relates to the use of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2- methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2,
  • PAH pulmonary arterial hypertension
  • IBS pulmonary arterial hypertension
  • IBD inflammatory bowel disease
  • urticaria dermatosis
  • atopic dermatitis allergic contact dermatitis
  • rheumatoid arthritis multiple sclerosis
  • melanoma a gastrointestinal stromal tumor
  • a mast cell tumor
  • the present invention relates to the use of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol
  • the present invention relates to the use of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol
  • the present invention relates to the use of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol
  • the present invention relates to the use of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol
  • the present invention relates to the use of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol
  • the present invention relates to the use of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3
  • PAH pulmonary arterial hypertension
  • IBS pulmonary arterial hypertension
  • IBD inflammatory bowel disease
  • urticaria dermatosis
  • atopic dermatitis allergic contact dermatitis
  • rheumatoid arthritis multiple sclerosis
  • melanoma a gastrointestinal stromal tumor
  • a mast cell tumor
  • the present invention relates to the use of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3
  • the present invention relates to the use of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3
  • the present invention relates to the use of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2- methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol
  • the present invention relates to the use of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3
  • the present invention relates to the use of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3
  • the present invention relates to a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-
  • PAH pulmonary arterial hypertension
  • IBS pulmonary arterial hypertension
  • IBD inflammatory bowel disease
  • urticaria dermatosis
  • atopic dermatitis allergic contact dermatitis
  • rheumatoid arthritis multiple sclerosis
  • melanoma a gastrointestinal stromal tumor
  • a mast cell tumor
  • the present invention relates to a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-
  • the present invention relates to a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-
  • the present invention relates to a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-
  • the present invention relates to a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-
  • the present invention relates to a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, the composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-
  • the present invention relates to a method of treating a mast-cell associated disease, a respiratory disease, an inflammatory disorder, irritable bowel syndrome (IBS) , inflammatory bowel disease (IBD) , an autoimmune disorder, a metabolic disease, a fibrosis disease, a dermatological disease, pulmonary arterial hypertension (PAH) and primary pulmonary hypertension (PPH) , comprising administering to a subject a therapeutically effective amount of a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1
  • the present invention relates to a method of treating asthma, allergic rhinitis, pulmonary arterial hypertension (PAH) , pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, scleroderma, irritable bowel syndrome (IBS) , inflammatory bowel disease (IBD) , urticaria, dermatosis, atopic dermatitis, allergic contact dermatitis, rheumatoid arthritis, multiple sclerosis, melanoma, a gastrointestinal stromal tumor, a mast cell tumor, mastocytosis, anaphylactic syndrome, type I diabetes or type II diabetes, comprising administering to a subject a therapeutically effective amount of a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N-
  • the present invention relates to a method of treating asthma or allergic rhinitis, comprising administering to a subject a therapeutically effective amount of a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N-
  • the present invention relates to a method of treating pulmonary arterial hypertension (PAH) , comprising administering to a subject a therapeutically effective amount of a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3- yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A
  • the present invention relates to a method of treating irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) , comprising administering to a subject a therapeutically effective amount of a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a]
  • the present invention relates to a method of treating urticaria, dermatosis, atopic dermatitis or allergic contact dermatitis, comprising administering to a subject a therapeutically effective amount of a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [
  • the present invention relates to a method of treating urticarial, comprising administering to a subject a therapeutically effective amount of a N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal, a composition comprising the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A or N- (5- (5- (5- ( (1
  • Example 1 Preparation of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide (2.0 g, e.g.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A according to the present invention was investigated by powder X-ray diffraction, which was performed with a Bruker D8 advance, Cu-Kalpha radiation (wavelength 0.15406 nm) and a Lynxeye (1 D) detector.
  • Diffractograms were recorded at a tube voltage of 40 kV and a current of 40 mA. Step size was 0.017° with a dwell time of 0.3s per step. Diffractograms were measured between 2-45 °2theta.
  • a typical precision of the 2-Theta values is in the range of ⁇ 0.2° 2-Theta, preferably of ⁇ 0.1° 2-Theta.
  • the diffraction peak of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A of the present invention at 5.0° 2-Theta can appear in the range of from 4.8 to 5.2° 2-Theta, preferably in the range of from 4.9 to 5.1° 2-Theta on most X-ray diffractometers under standard conditions.
  • a representative diffractogram of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A according to the present invention is displayed in figure 1 and the corresponding reflection list (peak list) from 3 to 30° 2-Theta and relative peak intensities are provided in table 1 below.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A according to the present invention was investigated by DSC, which was performed on a TA Discovery instrument A sample of approximately 2-4 mg was heated in an aluminum pan with pierced lid from 25 to 300 °C at a rate of 10 K/min. Nitrogen (50 mL/min) was used as purge gas.
  • the DSC curve of Form A (figure 2) shows a single endothermic peak with an onset temperature of about 175.0 °C and a peak temperature of about 175.2 °C, which is due to the melting of the sample.
  • the anhydrous and non-solvated nature of Form A and its excellent thermal stability are evidenced by the fact that neither phase changes nor desolvation events are detectable until the sample melts.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A according to the present invention was investigated by TGA, which was performed on a TA Discovery instrument. A sample of approximately 15 mg was heated in a 100 microliter aluminum pan closed with an aluminum lid. The lid was automatically pierced at the beginning of the measurement. The sample was heated from 30 to 300 °C at a rate of 10°C/min. Nitrogen (20 mL/min) was used as purge gas.
  • the TGA curve (figure 3) shows no significant mass loss until the sample melts. For example mass losses of only about 0.007 weight%up to a temperature of about 180 °C were observed, which further proves the presence of anhydrous and non-solvated Form A.
  • Example 5 Preparation of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA was obtained from Water activity evaluation-Crystal modification analysis (Example 13-7) .
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA according to the present invention was investigated by powder X-ray diffraction, which was performed with a Bruker D8 advance, Cu-Kalpha radiation (wavelength 0.15406 nm) and a Lynxeye (1 D) detector.
  • Diffractograms were recorded at a tube voltage of 40 kV and a current of 40 mA. Step size was 0.017° with a dwell time of 0.3s per step. Diffractograms were measured between 2-45 °2theta.
  • a typical precision of the 2-Theta values is in the range of ⁇ 0.2° 2-Theta, preferably of ⁇ 0.1° 2-Theta.
  • the diffraction peak of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA of the present invention at 6.4° 2-Theta can appear in the range of from 6.2 to 6.6° 2-Theta, preferably in the range of from 6.3 to 6.5° 2-Theta on most X-ray diffractometers under standard conditions.
  • a representative diffractogram of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA according to the present invention is displayed in figure 4 and the corresponding reflection list (peak list) from 3 to 45°2-Theta and relative peak intensities are provided in table 2 below.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA according to the present invention was investigated by DSC, which was performed on a TA Discovery instrument. A sample of approximately 2-4 mg was heated in an aluminum pan with pierced lid from 25 to 300 °C at a rate of 10 K/min. Nitrogen (50 mL/min) was used as purge gas.
  • the DSC curve of Form HA shows multiple thermal events, in particular melting at about 87 °C, followed by melting at about 125 °C, followed by recrystallization, melting at about 165 °C followed by recrystallization, and melting again with a final melting point of about 175 °C.
  • the first endotherm is dehydration followed by a melting and recrystallization (exotherm) and another melting/recrystallization event.
  • the final melting at 175 °C is likely identical to the melting of Form A.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HA according to the present invention was investigated by TGA, which was performed on a TA Discovery instrument. A sample of approximately 15 mg was heated in a 100 microliter aluminum pan closed with an aluminum lid. The lid was automatically pierced at the beginning of the measurement. The sample was heated from 30 to 300 °C at a rate of 10 °C/min. Nitrogen (20 mL/min) was used as purge gas.
  • the TGA curve (figure 6) revealed about 5%mass loss up to a temperature of about 112 °Cwhich further corresponds to dehydration before melting.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HB according to the present invention was investigated by powder X-ray diffraction, which was performed with with a Bruker D8 advance, Cu-Kalpha radiation (wavelength 0.15406 nm) and a Lynxeye (1 D) detector.
  • Diffractograms were recorded at a tube voltage of 40 kV and a current of 40 mA. Step size was 0.017° with a dwell time of 0.3s per step. Diffractograms were measured between 2-45 °2theta.
  • a typical precision of the 2-Theta values is in the range of ⁇ 0.2° 2-Theta, preferably of ⁇ 0.1° 2-Theta.
  • the diffraction peak of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HB of the present invention at 6.7° 2-Theta can appear in the range of from 6.5 to 6.9° 2-Theta, preferably in the range of from 6.6 to 6.8° 2-Theta on most X-ray diffractometers under standard conditions.
  • a representative diffractogram of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HB according to the present invention is displayed in figure 7 and the corresponding reflection list (peak list) from 3 to 45° 2-Theta and relative peak intensities are provided in table 3 below.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HB according to the present invention was investigated by DSC, which was performed on a TA Discovery instrument. A sample of approximately 2-4 mg was heated in an aluminum pan with pierced lid from 25 to 300 °C at a rate of 10 K/min. Nitrogen (50 mL/min) was used as purge gas.
  • the DSC curve of Form HB shows multiple thermal events, in particular melting at about 110 °C, followed by recrystallisation, melting at about 125 °C followed by recrystallization, melting at about 165 °C followed by recrystallization, and melting again with a final melting point of about 173 °C.
  • the first endotherm is dehydration followed recrystallization (exotherm) and then multiple conversion.
  • the final melting at 173 °C is likely identical to the melting of Form A.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form HB according to the present invention was investigated by TGA, which was performed on a TA Discovery instrument. A sample of approximately 15 mg was heated in a 100 microliter aluminum pan closed with an aluminum lid. The lid was automatically pierced at the beginning of the measurement. The sample was heated from 30 to 300 °C at a rate of 10°C/min. Nitrogen (20 mL/min) was used as purge gas.
  • the TGA curve (figure 9) revealed about 4.5%mass loss up to a temperature of about 100 °C which further corresponds to dehydration before melting.
  • Example 13-1 Evaluation of Humidty at elevated temperature
  • the samples were examined by XRPD for physical stability determination and by HPLC for chemical stability determination indicated by the presence of degradation products (DP) .
  • HPLC method used is
  • the color (CL) of the samples was evaluated by visual observation.
  • the samples were examined by XRPD for physical stability determination and by HPLC for chemical stability determination indicated by the presence of degradation products (DP) .
  • the HPLC method used is described in Example 13-1.
  • the color (CL) of the samples was evaluated by visual observation.
  • Example 13-3 Evaluation of Xenon light exposure
  • Example 13-4 Evaluation of the effecte of grinding and granulation
  • Example 13-6 Crystal modification after equilibration in water for 2 weeks
  • Table 6 provides solubility data of 5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Form A at 25 °C after 24 hours equilibration and the final pH of the sample.
  • Example 15 Preparation of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide (2.0 g, e.g. prepared according to the method disclosed in example F110 of WO 2013/033070 A1) and fumaric acid (310.7 mg, commercial sample from Sigma Aldrich) were mixed in a reactor and mechanically stirred while 40 mL of 2-propanol was added to the stirred powder mixture. The suspension was then heated to 70 °C or 3 hours under stirring. No clear solution was obtained. The suspension was then cooled to room temperature within 3 hours and continually stirred overnight.
  • Example 16 Powder X-ray diffraction
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal according to the present invention was investigated by powder X-ray diffraction, which was performed with a a Bruker D8 advance, Cu-Kalpha radiation (wavelength 0.15406 nm) and a Lynxeye (1 D) detector.
  • Diffractograms were recorded at a tube voltage of 40 kV and a current of 40 mA. Step size was 0.017° with a dwell time of 0.3s per step. Diffractograms were measured between 2-45 °2theta.
  • a typical precision of the 2-Theta values is in the range of ⁇ 0.2° 2-Theta, preferably of ⁇ 0.1°2-Theta.
  • the diffraction peak of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal of the present invention at 14.9° 2-Theta can appear in the range of from 14.7 to 15.1° 2-Theta, preferably in the range of from 14.6 to 15.0° 2-Theta on most X-ray diffractometers under standard conditions.
  • a representative diffractogram of the N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal according to the present invention is displayed in figure 10 and the corresponding reflection list (peak list) from 3 to 30° 2-Theta and relative peak intensities are provided in table 7 below.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal according to the present invention was investigated by DSC, which was performed on a TA Discovery instrument. A sample of approximately 2-4 mg was heated in an aluminum pan with pierced lid from 25 to 300 °C at a rate of 10 K/min. Nitrogen (purge rate 50 mL/min) was used as purge gas.
  • the differential scanning calorimetry curve (figure 11) shows a single endothermic peak with an onset temperature of about 227 °C and a peak temperature of about 229 °C, which is due to the melting of the sample.
  • the anhydrous and non-solvated nature of the co-crystal and its excellent thermal stability are evidenced by the fact that neither phase changes nor desolvation events are detectable until the sample melts.
  • N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal according to the present invention was investigated by TGA, which was performed on a TA Discovery instrument. A sample of approximately 15 mg was heated in a 100 microliter aluminum pan closed with an aluminum lid. The lid was automatically pierced at the beginning of the measurement. The sample was heated from 30 to 300 °C at a rate of 10°C/min. Nitrogen (purge rate 20 mL/min) was used as purge gas.
  • the TGA curve shows no significant mass loss until the sample melts. For example mass losses of only about 2 weight%up to a temperature of about 200 °C were observed, which further proves the presence of an anhydrous and non-solvated co-crystal.
  • Example 19 Stability of (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal
  • Example 19-1 Evaluation of Humidty at elevated temperature
  • the samples were examined by XRPD for physical stability determination and by HPLC for chemical stability determination indicated by the presence of degradation products (DP) .
  • HPLC method used is
  • the color (CL) of the samples was evaluated by visual observation.
  • the samples were examined by XRPD for physical stability determination and by HPLC for chemical stability determination indicated by the presence of degradation products (DP) .
  • the HPLC method used is described in Example 19-1.
  • the color (CL) of the samples was evaluated by visual observation.
  • Example 19-3 Evaluation of Xenon light exposure
  • Example 19-4 Evaluation of the effecte of grinding and granulation
  • Example 19-6 Crystal modification after equilibration in water for 2 weeks
  • Example 20 Solubility of 5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide Fumaric acid co-crystal
  • Table 10 provides solubility data of 5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide fumaric acid co-crystal at 25 °C after 24 hours equilibration and the final pH of the sample.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/CN2020/090060 2019-05-13 2020-05-13 Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide WO2020228746A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN202080050607.4A CN114096538A (zh) 2019-05-13 2020-05-13 N-(5-(5-((1r,2s)-2-氟环丙基)-1,2,4-噁二唑-3-基)-2-甲基苯基)咪唑并[1,2-a]吡啶-3-甲酰胺的结晶型
AU2020274564A AU2020274564A1 (en) 2019-05-13 2020-05-13 Crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide
MX2021013814A MX2021013814A (es) 2019-05-13 2020-05-13 Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida.
JP2021567913A JP2022533340A (ja) 2019-05-13 2020-05-13 Ｎ－（５－（５－（（１Ｒ，２Ｓ）－２－フルオロシクロプロピル）－１，２，４－オキサジアゾール－３－イル）－２－メチルフェニル）イミダゾ［１，２－ａ］ピリジン－３－カルボキサミドの結晶形態
US17/595,260 US20220194936A1 (en) 2019-05-13 2020-05-13 Crystalline forms of n-(5-(5-((1r,2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide
BR112021022685A BR112021022685A2 (pt) 2019-05-13 2020-05-13 Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4-oxadiazol-3-il)-2-metilfenil)imidazo[1,2-a]piridina-3-carboxamida
CA3139552A CA3139552A1 (en) 2019-05-13 2020-05-13 Crystalline forms of n-(5-(5-((1r,2s)-2-fluorocyclopropyl)-1, 2,4-oxadiazol-3-yl)-2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide
KR1020217040220A KR20220007650A (ko) 2019-05-13 2020-05-13 N-(5-(5-((1r,2s)-2-플루오로시클로프로필)-1,2,4-옥사디아졸-3-일)-2-메틸페닐)이미다조[1,2-a]피리딘-3-카르복스아미드의 결정질 형태
SG11202112281UA SG11202112281UA (en) 2019-05-13 2020-05-13 Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide
EP20805948.5A EP3969453A4 (en) 2019-05-13 2020-05-13 CRYSTALLINE FORMS OF N-(5-(5-((1R,2S)-2-FLUOROCYCLOPROPYL)-1,2,4-OXADIAZOL-3-YL)-2-METHYLPHENYL)IMIDAZO[1,2-A]PYRIDINE- 3-CARBOXAMIDE
IL287877A IL287877A (he) 2019-05-13 2021-11-07 צורות גבישיות של n-(5-(5-((1r,2s)-2-פלאורוציקלופרופיל)-1,2,4-אוקסאדיאזול-3-יל)-2-מתילפניל)אימידאזו[1 ,2-a]פירידינ-3-קרבוקסאמיד

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/086582 2019-05-13
CN2019086582 2019-05-13

Publications (1)

Publication Number Publication Date
WO2020228746A1 true WO2020228746A1 (en) 2020-11-19

Family

ID=73289607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/090060 WO2020228746A1 (en) 2019-05-13 2020-05-13 Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide

Country Status (14)

Country Link
US (1) US20220194936A1 (he)
EP (1) EP3969453A4 (he)
JP (1) JP2022533340A (he)
KR (1) KR20220007650A (he)
CN (1) CN114096538A (he)
AU (1) AU2020274564A1 (he)
BR (1) BR112021022685A2 (he)
CA (1) CA3139552A1 (he)
IL (1) IL287877A (he)
MA (1) MA55976A (he)
MX (1) MX2021013814A (he)
SG (1) SG11202112281UA (he)
TW (1) TW202108581A (he)
WO (1) WO2020228746A1 (he)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022016021A1 (en) * 2020-07-15 2022-01-20 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
WO2022109595A1 (en) * 2020-11-19 2022-05-27 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220175740A1 (en) * 2020-11-19 2022-06-09 Novartis Ag Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033203A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
WO2013033070A1 (en) * 2011-09-01 2013-03-07 Irm Llc COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
WO2013033167A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
WO2013033116A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033203A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
WO2013033070A1 (en) * 2011-09-01 2013-03-07 Irm Llc COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
WO2013033167A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
WO2013033116A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BABAEI, MARYAM ABBASPOUR ET AL.: "Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. 10, 31 December 2016 (2016-12-31), pages 2443 - 2459, XP055484967, DOI: 10.2147/DDDT.S89114 *
ROSKOSKI ROBERT JR.: "The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders", PHARMACOLOGICAL RESEARCH, vol. 133, 25 April 2018 (2018-04-25), pages 35 - 52, XP055678375, DOI: 10.1016/j.phrs.2018.04.020 *
See also references of EP3969453A4 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022016021A1 (en) * 2020-07-15 2022-01-20 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
US11767319B2 (en) * 2020-07-15 2023-09-26 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
WO2022109595A1 (en) * 2020-11-19 2022-05-27 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
US20220184045A1 (en) * 2020-11-19 2022-06-16 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
US11744823B2 (en) 2020-11-19 2023-09-05 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same

Also Published As

Publication number Publication date
TW202108581A (zh) 2021-03-01
BR112021022685A2 (pt) 2022-03-29
KR20220007650A (ko) 2022-01-18
EP3969453A1 (en) 2022-03-23
CA3139552A1 (en) 2020-11-19
MX2021013814A (es) 2022-02-10
MA55976A (fr) 2022-03-23
US20220194936A1 (en) 2022-06-23
SG11202112281UA (en) 2021-12-30
JP2022533340A (ja) 2022-07-22
AU2020274564A1 (en) 2021-12-09
IL287877A (he) 2022-01-01
CN114096538A (zh) 2022-02-25
EP3969453A4 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
WO2020228746A1 (en) Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide
CA3074529C (en) Co-crystal of roxadustat with l-proline and uses thereof
WO2020230028A1 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
US11603363B2 (en) Crystalline form of LNP023
JP2022534216A (ja) Ｂｔｋ阻害剤の結晶形態
US20220267334A1 (en) Crystalline forms of an orally available, selective kit and pdgfr kinase inhibitor
EP3808742A1 (en) Polymorph of selinexor
EP3239138A1 (en) Hydrogen fumarate salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
US20240059661A1 (en) Solid state forms of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
EP3887356B1 (en) Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
AU2019315778C1 (en) Crystalline forms of a LTA4H inhibitor
JP2024150466A (ja) Ｌｎｐ０２３の結晶形態

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20805948

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3139552

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021567913

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021022685

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20217040220

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020274564

Country of ref document: AU

Date of ref document: 20200513

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020805948

Country of ref document: EP

Effective date: 20211213

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021022685

Country of ref document: BR

Free format text: APRESENTAR A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DA PRIORIDADE CN PCT/CN2019/086582 DE 13/05/2019 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTA CONFORME O ART. 15 DA PORTARIA 39/2021. O DOCUMENTO APRESENTADO NAO ESTA TRADUZIDO E A DECLARACAO NAO CONTEM OS DADOS DA PRIORIDADE.

ENP Entry into the national phase

Ref document number: 112021022685

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211111